Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
about
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseaseCommon medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular safety of anti-diabetic drugsOptions for empagliflozin in combination therapy in type 2 diabetes mellitusSGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesEmpagliflozinHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic reviewSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureComparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysisBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Empagliflozin in the treatment of type 2 diabetes: evidence to dateSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsEffect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Short commentary on empagliflozin and its potential clinical impactThe role of empagliflozin in the management of type 2 diabetes by patient profile.Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 DiabetesManagement of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of NephropathySafety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusEmpagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisAn overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsPopulation Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
P2860
Q26739475-E452D472-8315-4F0F-9778-68B5AD672BD3Q26740253-BA98EA50-A2B5-49F2-92F2-3573BEDBC61FQ26741082-94BD8967-B372-4E01-AE1A-72AD4AE30DE3Q26745771-51D09136-6D95-4085-B834-81F9324A6D42Q26746901-141B4C3D-F7EE-4840-861C-B07B1A61F479Q26749281-3525A88E-7C3F-4567-811B-9A44FF9FFE61Q26773311-25256EFB-4F8F-4DB7-8483-DB812E8E3F32Q27301948-A25E4F1E-9E61-4154-84E2-F6778B04A60EQ28071386-4FF1B92E-BA5C-4ABD-898D-D8FE13AA4D29Q28072352-12B1808A-017F-46F3-94FF-E77BE908B81AQ28072765-6EA3E7BE-5143-4E54-A179-66189470D1A2Q28076978-7CFAA79E-7059-4375-AB87-E6458D569658Q28080114-29B7A50F-D958-4D20-9954-67D8E6D6ECE4Q28546797-B59828D3-5E0B-4C92-AB42-DD5C1BB151ACQ28553482-364BB782-9BF5-4880-903D-3984227EE5DDQ30249371-3A6693B1-CE26-4535-8814-34D24F2D8642Q31105792-4737A8B6-181C-470D-9C28-AB68882F1ADAQ31112303-ACB44BD3-C65D-4756-9B0D-8FC4D9C24100Q32186373-6D29D28A-62B6-4FF3-B08C-66379443E538Q33837017-C7D754E3-84C3-46E7-942B-371AA129E9BFQ33890770-A1F36995-DA2E-42EE-9D4D-6CEB8AF24840Q34502358-D6C944D7-3E9F-4F2F-AA9A-0989E89429C9Q34973750-BE54D831-7852-42E0-8375-4A5497D49138Q35117192-768C6033-91AD-4E70-A506-5F35AA146C8FQ35528797-B007D383-D181-4993-9184-FB0C5610C6B5Q35592873-5A9782ED-A3AC-400F-AA1D-50CAA988BF7AQ35911236-D537A2CB-1BF6-4AAC-BD52-634A6C928928Q36257565-B7306E81-ACA4-4B00-9F6A-DD43A5746976Q36333760-21E61205-D50C-42B8-A1AD-6410D65A1DDEQ36373688-21111B46-2228-4A55-BC31-DF2353176B0EQ36402095-12B82186-83AB-45E3-BB6C-C10C7759DABDQ36555418-F63B5EA6-0560-4DF8-95F4-67C915D5F240Q36592820-55A6F920-BDF7-43A6-B03B-1C6705F7D928Q36622125-03F56CB6-0A7E-493A-ABFB-173A14FB4F4CQ36960633-11D930C4-D02F-4EE7-8337-107C9323DA9AQ37030680-DF6ACE54-4BA5-4C32-B2B3-9B97DEC74CB7Q37114983-B07896F7-2762-4ED3-BF53-695C86B16D37Q37239278-D9D0A5E8-048A-4A7B-B1BA-3D60C4502B1CQ37279276-F4FA13BD-0EFF-482E-8B0F-F4C411AC8A65Q37325818-4E446500-0D96-449F-A586-8E6D3A3FFFFE
P2860
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@en
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@nl
type
label
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@en
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@nl
prefLabel
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@en
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@nl
P2093
P921
P356
P1433
P1476
Empagliflozin as add-on to met ...... ind, placebo-controlled trial.
@en
P2093
EMPA-REG MET Trial Investigators
Elke Seewaldt-Becker
Hans J Woerle
Ludwig Merker
Marc Weimer
Thomas Meinicke
Uli C Broedl
P304
P356
10.2337/DC13-2105
P407
P577
2014-04-10T00:00:00Z